People

	About us	R&D Projects	Media Centre	People	Contact
People Management: - Vincent Charlon - Christophe Reymond - Jean Paul Rohmer - François Spertini Scientific Advisory Board - Jean Michel Dayer - Raif S Geha - Stefan H Kaufmann - François Spertini	MANAGEMENT Vincent Charlon, PhD, Chief Executive Officer 20 years of global clinical development and management experience CEO LS Pharma International SA, drug repositioning startup, 2007-2008 CEO Hesperion Ltd., the clinical development CRO who conducted all initial trials for Actelion’s Tracleer® and later provided international clinical trials and consulting to >100 European and North American biotechs, 1998-2006 Director of Clinical Research, Hoffmann-La Roche (US and CH) 1990-1998, global clinical leader for bosentan, successful global NDA of POSICOR® for hypertension and angina pectoris
Board of Directors - Francois Spertini - Daniel Rey - Jean Paul Rohmer	Christophe Reymond, PhD, Chief Scientific Officer 20 years of biology, immunology, intellectual property and start-up experience COO/CEO Anergis SA 2005-2008 CSO Dictagene, a vaccine development biotech company, 2001-2005 Co-founder and Board Member Dictagene 1991-2001, including responsibility for all intellectual property and patent management Assistant Professor cell biology, Medical Faculty Lausanne, 1992-2001
	Jean Paul Rohmer, Strategic and Commercial Advisor 30 years of pharmaceutical marketing, sales, Managing director and founder, IDEFI Gestion, 2000-present; interim management and consulting for life science start-ups General manager/CEO Stallergenes SA (a world leader in specific immunotherapy) 1994-1999 General manager Pharmaceutical Division, LILLY FRANCE SA 1992-1994 Commercial and sales position 1979-1992 at Eli Lilly
	Francois Spertini, M.D. PhD, Medical Expert 20 years of medical practice & research in the fields of allergy and immunology Associate Professor, Chief of Allergy/Immunology, CHUV Lausanne 2003-present President and founder of Anergis
	SCIENTIFIC ADVISORY BOARD Jean-Michel Dayer, M.D. is Emeritus Professor of Medicine of the University of Geneva (2007). Dr. Dayer trained in Internal Medicine in Geneva. In 1974, he joined the Arthritis Unit, MGH, HMS (Professor S. M. Krane), Assistant Professor of Medicine in 1978. Back at the Faculty of Medicine in Geneva (1981), he was Head/ Division of Immunology & Allergy, Geneva University Hospital (1993), full Professor of Medicine (1996), Vice-Dean (1999) and Chairman of the Section of Clinical Medicine, Faculty of Medicine, Geneva (2004). Dr. Dayer was among the first to initiate the field of pro- and anti-inflammatory cytokines in chronic inflammatory diseases, and to establish a link between immune system, cytokines and matrix degradation. He identified the factor IL-1 and TNF which stimulates collagenase and PGE₂ in synovial cells, and unravelled the mechanism of its production - outcome of the interaction between monocytes and lymphocytes. He has 319 publications in peer-reviewed journals and numerous review articles and book chapters. Dr. Dayer received the Max Cloëtta Award, the Carol Nachman award the Novartis- ILAR Rheumatology, the EULAR Prize and the Japan Rheumatism Foundation International RA Award and presented the Heberden Lecture. He is Doctor honoris causa of Lund University (Sweden) and Honorary Member of the Italian Rheumatology Society. He was President of the European Cytokine Society, International Cytokine Society and Swiss Society of Allergy & Immunology, councillor within the Scientific Committee of the Swiss National Science Foundation, and is presently a member of the Scientific Committee of EULAR and Master of the American College of Rheumatology.
	Raif Salim Geha, M.D. received his M.D. degree in 1969 from the American University of Beirut, Lebanon, and trained in Pediatrics and Immunology at Boston Children’s Hospital and Harvard Medical School under a Fogarty International Fellowship. He became Head of the Division of Allergy at Children’s in 1976 and was appointed Professor of Pediatrics at Harvard Medical School in 1987, where he now holds the James L. Gamble chair of Pediatrics. Since 1988, he has headed the Combined Allergy, Immunology, Rheumatology and Dermatology Division at Children’s. Dr. Geha’s research interests are in the fields of primary immunodeficiencies, T cell activation, IgE isotype switching, and mechanisms of atopic dermatitis. He has contributed to date more than 315 original articles, 150 reviews, several monographs and a book. His publications have appeared in Cell, Immunity, Nature, Molecular Cell, PNAS, J. Experimental Medicine, J. of Immunol. and JACI. Dr. Geha has received the Mead Johnson Award for Pediatric Research, the Kuwait Foundation for the Advancement of Sciences Prize, and the Scientific Achievement Award from the International Association of Allergology and Clinical Immunology. He has served on a number of NIH study sections and on the NIAID council, has been a director of the American Board of Allergy and Immunology, was elected to the American Society of Clinical Investigation and the American Association of Physicians, has presided over the Clinical Immunology Society and chairs the IUIS Committee on Immunodeficiency. Over the past 25 years Dr. Geha has trained more than 100 postdoctoral fellows, many of whom have risen to leadership positions in the fields of allergy and Immunology.
	Stefan H.E. Kaufmann, Ph.D. is founding director and director of the Department of Immunology of the Max Planck Institute for Infection Biology in Berlin, professor for microbiology and immunology at the Charité, Humboldt University, Berlin, and honorary professor at the University Clinics Benjamin Franklin, Free University Berlin. Past president and honorary member of the German Society for Immunology. President of the European Federation of Immunological Societies. Vice President of the International Union of Immunological Societies (IUIS). Born 1948 in Ludwigshafen am Rhein. Studied biology at the Johannes Gutenberg University of Mainz, 1977 PhD. Scientific interests: immunity to bacterial pathogens with emphasis on tuberculosis and rational vaccine design. Numerous scientific awards. Doctor Honoris Causa from Université de la Mediterranée, Aix-Marseille II. More than 600 publications mostly in high-ranking journals. Highly cited immunologist (ISI Thomson).
	BOARD OF DIRECTORS Francois Spertini, M.D. PhD, President 20 years of medical practice & research in the fields of allergy and immunology Associate Professor, Chief of Allergy/Immunology, CHUV Lausanne 2003-present President and founder of Anergis
	Daniel Rey, Member 40 years finance experience Experience in finance management and raising capital Asset manager with Bayol Finance, Lausanne
	Jean Paul Rohmer, Member 30 years of pharmaceutical marketing, sales, Managing director and founder, IDEFI Gestion, 2000-present; interim management and consulting for life science start-ups General manager/CEO Stallergenes SA (a world leader in specific immunotherapy) 1994-1999 General manager Pharmaceutical Division, LILLY FRANCE SA 1992-1994 Commercial and sales position 1979-1992 at Eli Lilly